PMID- 21197274
OWN - NLM
STAT- MEDLINE
DCOM- 20110621
LR  - 20211020
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Print)
IS  - 1740-2522 (Linking)
VI  - 2010
DP  - 2010
TI  - Gene carriers and transfection systems used in the recombination of dendritic 
      cells for effective cancer immunotherapy.
PG  - 565643
LID - 10.1155/2010/565643 [doi]
LID - 565643
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells. They play a 
      vital role in the initiation of immune response by presenting antigens to T cells 
      and followed by induction of T-cell response. Reported research in animal studies 
      indicated that vaccine immunity could be a promising alternative therapy for 
      cancer patients. However, broad clinical utility has not been achieved yet, owing 
      to the low transfection efficiency of DCs. Therefore, it is essential to improve 
      the transfection efficiency of DC-based vaccination in immunotherapy. In several 
      studies, DCs were genetically engineered by tumor-associated antigens or by 
      immune molecules such as costimulatory molecules, cytokines, and chemokines. 
      Encouraging results have been achieved in cancer treatment using various animal 
      models. This paper describes the recent progress in gene delivery systems 
      including viral vectors and nonviral carriers for DC-based genetically engineered 
      vaccines. The reverse and three-dimensional transfection systems developed in DCs 
      are also discussed.
FAU - Chen, Yu-Zhe
AU  - Chen YZ
AD  - Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang 
      University, Hangzhou, Zhejiang 310058, China.
FAU - Yao, Xing-Lei
AU  - Yao XL
FAU - Tabata, Yasuhiko
AU  - Tabata Y
FAU - Nakagawa, Shinsaku
AU  - Nakagawa S
FAU - Gao, Jian-Qing
AU  - Gao JQ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20101220
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/genetics/immunology
MH  - Cancer Vaccines/genetics/immunology/*therapeutic use
MH  - Dendritic Cells/*immunology/metabolism
MH  - Genetic Vectors
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Interleukin-2/genetics/immunology
MH  - Models, Animal
MH  - Neoplasms/genetics/*immunology/*therapy
MH  - Recombination, Genetic
MH  - Transfection/*methods
PMC - PMC3010860
EDAT- 2011/01/05 06:00
MHDA- 2011/06/22 06:00
PMCR- 2010/12/20
CRDT- 2011/01/04 06:00
PHST- 2010/07/01 00:00 [received]
PHST- 2010/10/28 00:00 [accepted]
PHST- 2011/01/04 06:00 [entrez]
PHST- 2011/01/05 06:00 [pubmed]
PHST- 2011/06/22 06:00 [medline]
PHST- 2010/12/20 00:00 [pmc-release]
AID - 10.1155/2010/565643 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2010;2010:565643. doi: 10.1155/2010/565643. Epub 2010 Dec 20.